Cyclic ether vitamin D3 compounds and uses thereof

Details Cyclic ether vitamin D3 compounds and uses thereof Cyclic ether vitamin D3 compounds and uses thereof

1999-09-30

2000-09-19

McKane, Joseph

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

549416, 549417, 549356, 549428, 514460, A61K 31351, C07D30904

Patent

active

061213128

ABSTRACT:
Novel cyclic ether vitamin D3 compounds having a cyclic ether side chain are disclosed. These compounds were first identified as metabolites of 3-epi vitamin D3 produced via a tissue-specific metabolic pathway which catalyzes the formation of a cyclic ether structure. Also disclosed are 1.alpha.(OH) 3-epi vitamin D3 compounds, which are produced via the epimerization of a 3-.beta.-hydroxyl group of 1.alpha.(OH) vitamin D3 precursor in vivo. The vitamin D3 compounds of the present invention can be used as substitutes for natural and synthetic vitamin D3 compounds.

REFERENCES:
patent: 4021423 (1977-05-01), Baggiolini et al.
patent: 4038272 (1977-07-01), Partridge, Jr. et al.
patent: 4188345 (1980-02-01), DeLuca et al.
patent: 4206131 (1980-06-01), Salmond
patent: 4595776 (1986-06-01), Baggiolini et al.
patent: 4711881 (1987-12-01), Ikekawa
patent: 4804502 (1989-02-01), Baggiolini et al.
patent: 5145846 (1992-09-01), Baggiolini et al.
patent: 5206229 (1993-04-01), Calverley et al.
patent: 5206230 (1993-04-01), Ikekawa et al.
patent: 5389622 (1995-02-01), Posner et al.
patent: 5401733 (1995-03-01), McLane et al.
patent: 5428029 (1995-06-01), Doran et al.
patent: 5547947 (1996-08-01), Dore et al.
patent: 5789607 (1998-08-01), Okabe
patent: 5824811 (1998-10-01), Kubodera et al.
patent: 5830885 (1998-11-01), Posner
Muralidharam et al., Studies on the A-Ring Diastereomers of 1.alpha.,25-Dihydroxyvitamin D3. J. Org. Chem. 58(7) p. 1895-1899, 1993.
Baggiolini, E. et al., "Stereocontrolled Total Synthesis of 1.alpha.25-Dihydroxycholecalciferol and 1.alpha.,25-Dihydroxyergoacalciferol," J. Org. Chem., vol. 51, 3098-3108 (1986).
Bishop, J. et al., "Profile of Ligand Specificity of the Vitamin D Binding Protein for 1.alpha.,25-Dihydroxyvitamin D.sub.3 and its Analogs," Journal of Bone and Mineral Research, vol. 9, No. 1277-88 (1994).
Bouillon, R. et al., "Biologic Activity of Dihydroxylated 19-Nor-(Pre) Vitamin D.sub.3, " Journal of Bone and Mineral Research, vol. 8, No. 8, 1009-15 (1993).
Bouillon, R. et al., "Structure-Function Relationships in the Vitamin D Endocrine System," Endocrine Reviews, vol. 16, No. 2, 200-57 (1995).
Campbell, M. et al., "Vitamin D.sub.3 Analogs and Their 24-Oxo Metabolites Equally Inhibit Clonal Proliferation of a Variety of Cancer Cells but Have Differing Molecular Effects," Journal of Cellular Biochemistry, vol. 66, 413-25 (1997).
Cross, H. et al., "Vitamin D Metabolism in Human Colon Adenocarcinoma-derived Caco-2 Cells: Expression of 25-Hydroxyvitamin D.sub.3 -1.alpha.-hydroxylase Activity and Regulation of Side-chain Metabolism," J. Steroid Biochem. Molec. Biol., vol. 62, No. 1, 21-8 (1997).
de Vos, S. et al., "Effects of Potent Vitamin D.sub.3 Analogs on Clonal Proliferation of Humand Prostate Cancer Cell Lines," The Prostate, vol. 31, No. 2, 77-83 (1997).
Dusso, A.S. et al., "On the Mechanisms for the Selective Action of Vitamin D Analogs," Endocrinology, vol. 128, No. 4, 1687-92 (1991).
Fioravanti, L. et al., "Synthetic Analogs of Vitamin D.sub.3 Have Inhibitory Effects on Breast Cancer Cell Lines," Anticancer Research, vol. 18, 1703-8 (1998).
Fleet, J. et al., "1.alpha.,25-(OH).sub.2 -Vitamin D.sub.3 Analogs with Minimal in Vivo Calcemic Activity Can Stimulate Significant Transepithelial Calcium Transport and mRNA Expression in Vitro," Archives of Biochemistry and Biophysics, vol. 329, No. 2, 228-34 (1996).
Fleet, J.C. et al., "Effect of A-Ring Diastereomers of 1.alpha.,25-Dihydroxy Vitamin D.sub.3 on Calcium Transport in Caco-2 Cells," FASEB J., vol. 9, No. 3, 168 (1995). (Abstract).
Gardner, J. et al., "Vitamin D Analog 25-(OH)-16,23E-Diene-26,27-Hexafluoro-Vitamin D.sub.3 Induces Differentiation of HL60 Cells with Minimal Effects on Cellular Calcium Homeostasis," Journal of Cellular Biochemistry, vol. 63, 500-12 (1996).
Jung, S. et al., "1,25(OH).sub.2 -16ENE-Vitamin D.sub.3 is a Potent Antileukemic Agent with Low Potential to Cause Hypercalcemia," Leukemia Research, vol. 18, No. 6, 453-63 (1994).
Kim, H. et al., "1,25-Dihydroxy-Vitamin-D.sub.3 Enhances Antiproliferative Effect and Transcription of TGF-.beta.1 on Human Keratinocytes in Culture," Journal of Cellular Physiology, vol. 151, 579-87 (1992).
Lemire, J. et al., "1,25-Dihydroxy-24-OXO-16ene-Vitamin D3, a Renal Metabolite of the Vitamin D Analog 1,25-Dihydroxy-16ene-vitamin D3, Exerts Immunosuppressive Activity Equal to its Parent Without Causing Hypercalcemia in vivo," Endocrinology, vol. 135, No. 6, 2818-21 (1994).
Mayer, E. et al., "23,25-Dihydroxy-24-oxovitamin D.sub.3 :A Metabolite of Vitamin D.sub.d3 Made in the Kidney," Biochemistry, vol. 22, No. 8, 1798-1805 (1983).
Norman, A. et al., "Demonstration That 1.beta.,25-Dihydroxyvitamin D.sub.3 is an Antagonist of the Nongenomic buy not Genomic Biological Responses and Biological Profile of the Three A-ring Diasteromers of 1.alpha.,25-Dihydroxyvitamin D.sub.3," Journal of Biological Chemistry, vol. 268, No. 27, 20022-30 (1993).
Reddy, G.S. and Tserng, KY, "Calcitroic Acid, End Product of Renal Metabolism of 1,25-Dihydroxyvitamin D.sub.3 Through C-24 Oxidation Pathway," Biochemistry, vol. 28, 1763-9 (1989).
Reddy, G.S. et al., "Metabolism of 1.alpha.,25-Dihydroxyvitamin D.sub.3 and One of its A-Ring Diastereomer 1.alpha.,25-Dihydroxy-3-Epivitamin D.sub.3 in Neonatal Human Keratinocytes," Vitamin D: A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications, Prodeedings of the Ninth Workshop on Vitamin D, Orlando, Fl., 172-3 (May 28-Jun. 2, 1994).
Reddy, G.S. et al., "Stimulation of 24R,25-dihydroxyvitamin D.sub.3 Synthesis by Metabolites of Vitamin D.sub.3," Am. J. Physiol., vol. 245, No. 4, E359-64 (1983).
Reddy, G.S. et al., "Study of 1,25-Dihydroxyvitamin D.sub.3 Induced Alterations in the Metabolism of [.sup.3 H]25-Hydroxyvitamin D.sub.3 Using Isolated Perfused Kidneys From D-Sufficient Rats," Biochemical and Biophysical Research Communications, vol. 107, No. 3, 922-8 (1982).
Reichel, H. and Norman, A., "Systemic Effects of Vitamin D," Ann. Rev. Med., vol. 40, 71-8 (1989).
Schwartz, G. et al., "1,25-Dihydroxy-16-ENE-23-YNE-Vitamin D.sub.3 and Prostate Cancer Cell Proliferation in Vivo," Urology, vol. 46, No. 3, 365-9 (1995).
Siu-Caldera, ML et al., "The Enhanced Biological Activities Ascribed to its Parent Analog, 1.alpha.,25(OH).sub.2 -16-ene-D.sub.3 " J. Steroid Biochem. Molec. Biol., vol. 59, No. 5/6, 405-12 (1996).
Veyron, P. et al., "New 20-Epi-Vitamin D3 Analogs: Immunosuppressive Effects on Skin Allograft Survival," Transplantation Proceedings, vol. 27, No. 1, 450 (1995).

Affiliated with

Also associated with

Rating

Cyclic ether vitamin D3 compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic ether vitamin D3 compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic ether vitamin D3 compounds and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1073713